Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: A prospective 2-year study

Clinical Rheumatology

Volumn 32, Issue 3, 2013, Pages 377-381

  Dischereit, Gabriel ^a,b   Tarner, Ingo H ^a,b   Müller Ladner, Ulf ^a,b   Lange, Uwe ^a,b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b KERCKHOFF HEART CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,25 HYDROXYCHOLECALCIFEROL; C REACTIVE PROTEIN; CALCIFEDIOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; OSTEOCALCIN; PREDNISOLONE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE DENSITY; BONE METABOLISM; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; FEMALE; FEMUR NECK; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE DENSITY; FEMALE; FEMUR; HUMANS; LONGITUDINAL STUDIES; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PAIN MEASUREMENT; PILOT PROJECTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876666980     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2128-8     Document Type: Article

References (17)

1. Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23-27
2. Lange U, Teichmann J, Obermayer-Pietsch B (2009) Genetic aspects of osteopenia/osteoporosis in ankylosing spondylitis. Z Orthop Unfall 147:577-581
3. Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG (1989) Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 48:535-538
4. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 62:347-349
5. Lange U, Teichmann J, Müller-Ladner U, Strunk J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology 44:1546-1548
6. Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia I (1997) Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 99:1699-1703
7. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS et al (2012) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 71(Suppl II):i2-i45
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
9. Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
10. Lange U, Boss B, Teichmann J, Stracke H, Neeck G (2000) Bone mineral density and biochemical markers of bone metabolism in late onset rheumatoid arthritis and polymyalgia rheumatica - a prospective study on the influence of glucocorticoid therapy. Z Rheumatol 59(Suppl 2):II/137-II/141
11. Star VL, Hochberg MC (1994) Osteoporosis in patients with rheumatic diseases. Rheum Dis Clin N Am 20:561-576
12. Oelzner P, Muller A, Deschner F, Hüller M, Abendroth K, Hein G, Stein G (1998) Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 62:193-198
13. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ et al (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495-1499
14. Eekman DA, Vis M, Bultink IEM, Kuik DJ, Voskuyl AE, Dijkmans BAC, Lems WF (2011) Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:389-390
15. Kimble RB, Bain S, Pacifici R (1997) The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 12:935-941
16. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124
17. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C (2007) Miossec P (2007) A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9:R61